GO
Loading...

Enter multiple symbols separated by commas

Stocks Bristol-Myers Squibb Co

More

  • Pfizer Inc, which is lagging rivals in the lucrative field of cancer immunotherapies, has been the first to report early data of an "accelerator" treatment that targets a protein called 4-1 BB. Bristol-Myers Squibb Co is hot on Pfizer's heels with a handful of early-stage trials of its own 4-1 BB antibody. Holbrook Kohrt, a researcher from Stanford University...

  • Cramer Remix: Here's the problem with Apple Tuesday, 4 Aug 2015 | 7:03 PM ET
    Jim Cramer speaks with Apple Inc. CEO Tim Cook on the 10th Anniversary of Mad Money.

    The “Mad Money” host Jim Cramer gives his take on Apple’s recent decline.

  • Cramer: Rare biotechs that stumped me Tuesday, 4 Aug 2015 | 6:35 PM ET
    Biotech pharma

    Jim Cramer went back to the drawing board and presented his research on the rare biotechs that stumped him last month.

  • Data from Thomson Reuters published on Tuesday showed the number of innovative medicines, or new molecular entities, launched globally in 2014 hit a 17- year high of 46, up from 29 in 2013.. Phase III terminations totalled 56 in the last three years, down from 68 in 2009-2011, according to the Thomson Reuters 2015 CMR Pharmaceutical R&D Factbook.

  • *Worldwide cancer drug spending $100 billion in 2014. LONDON, Aug 3- New cancer drug cocktails set to reach the market in the next few years will test the limits of premium pricing for life-saving medicines, forcing company executives to consider fresh market strategies. Pricey immunotherapies, offering long-lasting responses, are already starting to change...

  • July 24- The U.S. Food and Drug Administration on Friday approved two treatments for less common forms of hepatitis C virus infections. The regulator cleared AbbVie Inc's Technivie, which targets HCV genotype 4 infections, and Bristol-Myers Squibb Co's Daklinza, used to treat HCV genotype 3 infections. Technivie, includes the same cocktail of drugs that...

  • LONDON, July 24- British spirits maker Diageo is under scrutiny in the United States, where the U.S. Securities and Exchange Commission has asked for information to see whether it shipped excess inventory to U.S. distributors, a practice known as "channel stuffing". A spokeswoman for Diageo, the world's biggest spirits company with brands including Smirnoff...

  • July 23- Bristol-Myers Squibb Co on Thursday reported far better than expected quarterly results thanks largely to delayed reimbursement for two hepatitis C treatments in France and demand for other leading company medicines. The company said it lost $130 million, or 8 cents per share, in the period. Company revenue rose 7 percent to $4.16 billion, about $400...

  • July 23- Bristol-Myers Squibb Co reported far better than expected quarterly results thanks largely to delayed reimbursement for two hepatitis C treatments in France and demand for other leading company medicines. The U.S. drugmaker, which raised its full-year profit forecast because of the strong second-quarter results, on Thursday said it lost $130...

  • Roche CEO warns on high pharma valuations Thursday, 23 Jul 2015 | 6:26 AM ET

    Valuation are "very high" in the pharmaceutical sector, Roche CEO Severin Schwan told CNBC on Thursday after the company posted a rise in sales.

  • Brace yourself! Thursday is earnings palooza Thursday, 23 Jul 2015 | 6:13 AM ET
    Trader on the floor of the New York Stock Exchange.

    Amazon.com, Caterpillar, McDonald's and GM are among the 50 odd companies reporting Thursday, making it the busiest day of the earnings season.

  • July 23- Switzerland's Roche is lining up more new drugs to drive sales in a two-year window before cheap copycats of its biotech medicines hit the market, including a promising cancer immunotherapy it hopes to launch by late 2016.. The shares rose 1.1 percent by 0920 GMT on Thursday, with Deutsche Bank analyst Tim Race describing the results as "a modest positive."

  • July 23- Switzerland's Roche expects no copycat competition to its biotech cancer drugs for another two years, giving it space to grow a successful portfolio of new and established medicines. The shares rose 1.5 percent in early trading on Thursday, with Deutsche Bank analyst Tim Race describing the results as "a modest positive." Its three top-selling cancer...

  • Brace yourself! Thursday is earnings palooza Wednesday, 22 Jul 2015 | 6:35 PM ET
    Trader on the floor of the New York Stock Exchange.

    Amazon.com, Caterpillar, McDonald's and GM are among the 50 odd companies reporting Thursday, making it the busiest day of the earnings season.

  • July 21- Novartis remains bullish about prospects for its blockbuster cancer drug Afinitor, which achieved sales of $1.58 billion last year, despite competitors lining up to challenge its market position. The success of Opdivo could, therefore, push back the use of Afinitor as doctors try the newer option, reducing sales of the Novartis product.

  • July 20- Bristol-Myers Squibb Co's Opdivo, a new oncology drug that makes cancer cells more susceptible to the immune system, on Monday won European approval to treat a form of lung cancer and was also found to be beneficial in patients with advanced kidney cancer. Bristol-Myers shares rose 1.2 percent after the favorable separate announcements involving the...

  • Four stocks to watch as day winds down Monday, 20 Jul 2015 | 1:31 PM ET

    The "Halftime Report" traders give their trades for the second half.

  • July 20- Bristol-Myers Squibb Co said a late-stage trial of its drug, Opdivo, was stopped early after the immunotherapy was found to be effective in patients with the most common form of kidney cancer. The drug competes with Merck& Co's Keytruda. AstraZeneca Plc, Pfizer Inc and other drugmakers are also developing PD-1 inhibitors, or similar drugs known as PD-L1...

  • Bristol's Opdivo found effective in kidney cancer Monday, 20 Jul 2015 | 8:30 AM ET

    July 20- Bristol-Myers Squibb Co said a late-stage trial testing Opdivo was stopped early after it was found beneficial in patients with the most common form of kidney cancer. An independent data committee recommended the trial be stopped, after it concluded that patients receiving Opdivo showed superior overall survival, compared to those who did not.

  • Your first trade for Tuesday Monday, 6 Jul 2015 | 6:13 PM ET
    Fast Money Final Trade: LLY, TLT, WTW & BMY

    The "Fast Money" traders give their final trades of the day.